Acoramidis

Acoramidis is a prescription medication indicated for cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

• Acoramidis is available under the following different brand names: Attruby.

Common side effects of Acoramidis include:

• abdominal pain
• diarrhea 

Serious side effects of Acoramidis include:

• not available

Rare side effects of Acoramidis include:

• none 

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, coordination loss, unsteady, very stiff muscles, high fever, profuse sweating, or tremors.
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights.
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out.

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult dosage

Tablet

• 356 mg

Transthyretin amyloid cardiomyopathy

Adult dosage

• 712 mg (2 tablets) orally two times a day

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

• Acoramidis has no noted severe interactions with any other drugs
• Acoramidis has no noted serious interactions with any other drugs
• Acoramidis has no noted moderate interactions with any other drugs
• Acoramidis has no noted minor interactions with any other drugs

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all the products you use. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, health questions, or concerns.

Contraindications

• None

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Acoramidis?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Acoramidis?”

Cautions

• Drug interaction overview
  • UGT inducers
    • Avoid coadministration
    • Acoramidis is metabolized by UGT enzyme-mediated glucuronidation
    • Coadministration with UGT inducers can potentially decrease acoramidis exposure
  • Strong CYP3A inducers
    • Avoid coadministration
    • Although acoramidis is not metabolized by CYP3A, strong CYP3A inducers can induce UGT enzymes
    • Acoramidis is metabolized by UGT enzyme-mediated glucuronidation
  • Sensitive CYP2C9 substrates
    • Acoramidis inhibits CYP2C9 and may increase CYP2C9 substrate concentrations if coadministered
    • Consider more frequent monitoring for increased exposure of CYP2C9 substrates

Pregnancy and Lactation

• Data are insufficient regarding use in pregnant women to establish a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes
• Report pregnancies to BridgeBio at 1-844-550-2246
• Lactation
  • Data are unavailable on the presence of acoramidis in either human or animal milk or the effects of the drug on breastfed infants or maternal milk production
  • Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for acoramidis and any potential adverse effects on breastfed children from the drug or the underlying maternal condition